Allogene Therapeutics, Inc.

Allogene Therapeutics, Inc.verified

ALLO

Price:

$2.77

Market Cap:

$473.26M

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A, which is in Phase I/II clinical trial for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. In addi...[Read more]

Industry

Biotechnology

IPO Date

2018-10-11

Stock Exchange

NASDAQ

Ticker

ALLO

The PE Ratio as of May 2024 (TTM) for Allogene Therapeutics, Inc. (ALLO) is -1.56

According to Allogene Therapeutics, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -1.56. This represents a change of -30.12% compared to the average of -2.23 of the last 4 quarters.

Allogene Therapeutics, Inc. (ALLO) Historical PE Ratio (quarterly & annually)

How has ALLO PE Ratio performed in the past?

The mean historical PE Ratio of Allogene Therapeutics, Inc. over the last ten years is -6.21. The current -1.56 PE Ratio has changed 2.41% with respect to the historical average. Over the past ten years (40 quarters), ALLO's PE Ratio was at its highest in in the December 2023 quarter at -1.57. The PE Ratio was at its lowest in in the December 2017 quarter at -137535.23.

Quarterly (TTM)
Annual

Average

-6.21

Median

-3.69

Minimum

-14.22

Maximum

0

Allogene Therapeutics, Inc. (ALLO) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Allogene Therapeutics, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 285.89%

Maximum Annual PE Ratio = 0

Minimum Annual Increase = -Infinity%

Minimum Annual PE Ratio = -14.22

Quarterly (TTM)
Annual
YearPE RatioChange
2023-1.54-43.62%
2022-2.73-67.02%
2021-8.28-36.40%
2020-13.01-8.51%
2019-14.22285.89%
2018-3.69-Infinity%

Allogene Therapeutics, Inc. (ALLO) Average PE Ratio

How has ALLO PE Ratio performed in the past?

The current PE Ratio of Allogene Therapeutics, Inc. (ALLO) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

3-year avg

-4.18

5-year avg

-7.96

10-year avg

-6.21

Allogene Therapeutics, Inc. (ALLO) PE Ratio vs. Peers

How is ALLO’s PE Ratio compared to its peers?

Allogene Therapeutics, Inc.’s PE Ratio is greater than G1 Therapeutics, Inc. (-7.73), greater than Heron Therapeutics, Inc. (-5.98), greater than Annexon, Inc. (-4.40), less than Sangamo Therapeutics, Inc. (-0.36), greater than Beam Therapeutics Inc. (-14.93), greater than Sana Biotechnology, Inc. (-6.15), greater than Caribou Biosciences, Inc. (-2.63), greater than Editas Medicine, Inc. (-2.77), greater than Theseus Pharmaceuticals, Inc. (-3.19), greater than aTyr Pharma, Inc. (-2.45), greater than Relay Therapeutics, Inc. (-2.64), less than Century Therapeutics, Inc. (-1.40), greater than Blueprint Medicines Corporation (-22.42), greater than Intellia Therapeutics, Inc. (-5.16), greater than Verve Therapeutics, Inc. (-2.53), greater than Prime Medicine, Inc. (-3.62), greater than iTeos Therapeutics, Inc. (-4.78), greater than Icosavax, Inc. (-8.27), greater than Mirati Therapeutics, Inc. (-5.32), greater than VectivBio Holding AG (-7.94),

Build a custom stock screener for Allogene Therapeutics, Inc. (ALLO) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Allogene Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Allogene Therapeutics, Inc. (ALLO) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Allogene Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the PE Ratio?

How can you use the PE Ratio?

What is Allogene Therapeutics, Inc.'s PE Ratio?

How is the PE Ratio calculated for Allogene Therapeutics, Inc. (ALLO)?

What is the highest PE Ratio for Allogene Therapeutics, Inc. (ALLO)?

What is the 3-year average PE Ratio for Allogene Therapeutics, Inc. (ALLO)?

What is the 5-year average PE Ratio for Allogene Therapeutics, Inc. (ALLO)?

How does the current PE Ratio for Allogene Therapeutics, Inc. (ALLO) compare to its historical average?